Federal Pharmaceutical Rises Over 3% in Intraday Trading as Weekly Long-Acting Insulin Candidate UBT38006 Injection Receives Clinical Trial Approval

Deep News05-08

Federal Pharmaceutical (03933) saw its shares rise more than 3% during intraday trading. At the time of writing, the stock was up 2.44%, trading at HK$10.09, with a turnover of HK$39.2058 million.

On May 7, Federal Pharmaceutical announced that UBT38006 injection, a Class 1 innovative drug independently developed by its wholly-owned subsidiary, Federal Biotech (Zhuhai Hengqin) Co., Ltd., has received implicit clinical trial approval from the China National Medical Products Administration. This approval marks another significant innovation achievement for the company in the field of diabetes treatment.

UBT38006 injection is a novel long-acting insulin weekly formulation with a unique molecular structure. The drug exerts its glucose-lowering pharmacological effects by specifically binding to the human insulin receptor. Compared to existing insulin products, the most notable advantage of UBT38006 lies in its unique molecular design, which enables reversible binding to human albumin, significantly extending the drug's half-life. Based on preclinical animal data, it is estimated that a once-weekly dosing regimen could be achieved in humans. The development of UBT38006 is expected to greatly enhance medication adherence for diabetes patients, reduce the treatment burden associated with frequent injections, and improve patients' quality of life.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1120779705?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-08 10:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1120779705","market":"other","top_or_hot":-1,"title":"Federal Pharmaceutical Rises Over 3% in Intraday Trading as Weekly Long-Acting Insulin Candidate UBT38006 Injection Receives Clinical Trial Approval","media":"Deep News","content":"<p>Federal Pharmaceutical (03933) saw its shares rise more than 3% during intraday trading. At the time of writing, the stock was up 2.44%, trading at HK$10.09, with a turnover of HK$39.2058 million.</p>\n<p>On May 7, Federal Pharmaceutical announced that UBT38006 injection, a Class 1 innovative drug independently developed by its wholly-owned subsidiary, Federal Biotech (Zhuhai Hengqin) Co., Ltd., has received implicit clinical trial approval from the China National Medical Products Administration. This approval marks another significant innovation achievement for the company in the field of diabetes treatment.</p>\n<p>UBT38006 injection is a novel long-acting insulin weekly formulation with a unique molecular structure. The drug exerts its glucose-lowering pharmacological effects by specifically binding to the human insulin receptor. Compared to existing insulin products, the most notable advantage of UBT38006 lies in its unique molecular design, which enables reversible binding to human albumin, significantly extending the drug's half-life. Based on preclinical animal data, it is estimated that a once-weekly dosing regimen could be achieved in humans. The development of UBT38006 is expected to greatly enhance medication adherence for diabetes patients, reduce the treatment burden associated with frequent injections, and improve patients' quality of life.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Federal Pharmaceutical Rises Over 3% in Intraday Trading as Weekly Long-Acting Insulin Candidate UBT38006 Injection Receives Clinical Trial Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFederal Pharmaceutical Rises Over 3% in Intraday Trading as Weekly Long-Acting Insulin Candidate UBT38006 Injection Receives Clinical Trial Approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2026-05-08 10:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Federal Pharmaceutical (03933) saw its shares rise more than 3% during intraday trading. At the time of writing, the stock was up 2.44%, trading at HK$10.09, with a turnover of HK$39.2058 million.</p>\n<p>On May 7, Federal Pharmaceutical announced that UBT38006 injection, a Class 1 innovative drug independently developed by its wholly-owned subsidiary, Federal Biotech (Zhuhai Hengqin) Co., Ltd., has received implicit clinical trial approval from the China National Medical Products Administration. This approval marks another significant innovation achievement for the company in the field of diabetes treatment.</p>\n<p>UBT38006 injection is a novel long-acting insulin weekly formulation with a unique molecular structure. The drug exerts its glucose-lowering pharmacological effects by specifically binding to the human insulin receptor. Compared to existing insulin products, the most notable advantage of UBT38006 lies in its unique molecular design, which enables reversible binding to human albumin, significantly extending the drug's half-life. Based on preclinical animal data, it is estimated that a once-weekly dosing regimen could be achieved in humans. The development of UBT38006 is expected to greatly enhance medication adherence for diabetes patients, reduce the treatment burden associated with frequent injections, and improve patients' quality of life.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03933","symbol_name":"联邦制药","start_time":0,"source_url":"","article_id":"1120779705","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1120779705","pubTimestamp":1778208031,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"Federal Pharmaceutical (03933) saw its shares rise more than 3% during intraday trading. At the time of writing, the stock was up 2.44%, trading at HK$10.09, with a turnover of HK$39.2058 million. On...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03933":"联邦制药","BK1191":"制药"},"translate_title":"每周长效胰岛素候选药物UBT38006注射液获临床试验批准，联邦制药盘中涨超3%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03933":1},"content_text":"Federal Pharmaceutical (03933) saw its shares rise more than 3% during intraday trading. At the time of writing, the stock was up 2.44%, trading at HK$10.09, with a turnover of HK$39.2058 million.\nOn May 7, Federal Pharmaceutical announced that UBT38006 injection, a Class 1 innovative drug independently developed by its wholly-owned subsidiary, Federal Biotech (Zhuhai Hengqin) Co., Ltd., has received implicit clinical trial approval from the China National Medical Products Administration. This approval marks another significant innovation achievement for the company in the field of diabetes treatment.\nUBT38006 injection is a novel long-acting insulin weekly formulation with a unique molecular structure. The drug exerts its glucose-lowering pharmacological effects by specifically binding to the human insulin receptor. Compared to existing insulin products, the most notable advantage of UBT38006 lies in its unique molecular design, which enables reversible binding to human albumin, significantly extending the drug's half-life. Based on preclinical animal data, it is estimated that a once-weekly dosing regimen could be achieved in humans. The development of UBT38006 is expected to greatly enhance medication adherence for diabetes patients, reduce the treatment burden associated with frequent injections, and improve patients' quality of life.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1120779705","isCrawlerRequest":true}